This is the narrative sold to new investors who joined in the bull run (including me)
What is that expertise Mr. Puri has in Pharma that can benefit Solara ? He was a banker , all his life he worked in this sector. At max he can bring in some good investors with big pockets or he invests his own money (which he already did in Stelis )
He is there in Strides / Stelis and then in Solara
Mr. Arun Kumar known for doing profitable sell outs now struggling all his current and past entities are struggling
Sequent, Strides and Solara
Forget about the inventory write-off , how come a well managed company can see such kind of degrowth ?
Pure Ibuprofen commodity play like IOLCP maintained the top line
Where as Solara , the narrative CDMO, niche molecules can see such kind of de-growth ?
So next time if I come across CDMO, CRO, CRAMS then I don’t have to be super excited, certainly these are niche spaces but they cannot generate steady regular income in the longer cycles only pure plays like PI or DIVIS kind of companies has such kind of expertise, hence they continue to demonstrate their strengths and market is rewarding them very richly
With these kind of numbers now we can say Solara dependency on commodity chemicals is very high .